SLN (Silence Therapeutics Plc American Depository Share) Stock Analysis - SEC Filings

Silence Therapeutics Plc American Depository Share (SLN) is a publicly traded Healthcare sector company. As of May 20, 2026, SLN trades at $6.24 with a market cap of $294.27M and a P/E ratio of -11.51. SLN moved +7.97% today. Year to date, SLN is +5.23%; over the trailing twelve months it is +21.40%. Its 52-week range spans $1.97 to $20.48. Analyst consensus is buy with an average price target of $27.59. Rallies surfaces SLN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find SLN SEC filings?

Rallies organizes SLN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

SLN Key Metrics

Key financial metrics for SLN
MetricValue
Price$6.24
Market Cap$294.27M
P/E Ratio-11.51
EPS$-0.54
Dividend Yield0.00%
52-Week High$20.48
52-Week Low$1.97
Volume158.89K
Avg Volume0
Revenue (TTM)$839.00K
Net Income$-75.04M
Gross Margin79.50%

SLN Analyst Consensus

5 analysts cover SLN: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $27.59.

Common questions about SLN

Where can I find SLN SEC filings?
Rallies organizes SLN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show SLN 10-K and 10-Q filings?
Rallies organizes SLN SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is SLN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SLN. It does not provide personalized investment advice.
SLN

SLN